Effect of interleukin 2 on killer cell inhibitory receptors in patients with rheumatoid arthritis

T Kogure, A Niizawa, L X Hai, H Fujinaga, Y Shimada, H Ochiai, K Terasawa

Abstract

Objective—The genes for killer cell inhibitory receptors (KIRs) have been cloned and their functions and responses to other molecules, including cytokines, have been partially clarified. However, the expression of KIRs has not been analysed in patients with autoimmune diseases, such as rheumatoid arthritis (RA), who are highly susceptible to microbial infection. Therefore, KIR expression on lymphocytes in patients with RA, and the regulation of KIR expression by interleukin 2 (IL2) in RA was investigated.

Methods—CD158a/b expression on peripheral blood mononuclear cells (PBMC) obtained from 25 patients with RA and 14 healthy subjects was analysed by flow cytometry. Additionally, PBMC from the two groups of subjects were cultured in RPMI 1640 medium with or without IL2 for 48 hours, and then their CD158a/b expression was analysed.

Results—The rate of CD158a expression on the CD8+ cells was lower in patients with RA than in healthy subjects, though there was no significant difference in the CD158a/b expression on the CD16+ cells between the two groups. The upregulation of CD16+CD158a/b+ cells in response to IL2 was significantly reduced in patients with RA compared with healthy subjects.

Conclusion—The reduced induction of KIR expression in response to IL2 may provide insight into the reason for the high susceptibility of patients with RA to microbial infection.

(Ann Rheum Dis 2001;60:166–169)

In 1995 the molecular cloning of novel natural killer (NK) receptors was reported, and it was subsequently shown that the receptors transmit negative signals. These receptors are now called killer cell inhibitory receptors (KIRs). It is widely accepted that the expression of KIRs plays a part in the cytotoxic function of NK cells. Analysis of KIR expression has contributed to determining the mechanism of NK cytotoxicity.

Several monoclonal antibodies to KIRs have been established. Antibody EB6 (anti-CD158a) reacts with KIR2DL1 and KIR2DS1, and GL183 (anti-CD158b) reacts with KIR2DL2, KIR2DL3, and KIR2DS2. KIR2DL1, 2, and 3 each contain an immunoreceptor tyrosine based inhibition motif. KIR2DL1 recognises HLA-Cw4, 5, 6, and KIR2DL2, 3 recognise HLA-Cw1, 3, 7. Using these monoclonal antibodies, we have recently shown that the expression of both CD158a and CD158b on lymphocytes is upregulated by interleukin 2 (IL2) but not by interferon γ or IL4, though IL2 enhances the cytotoxicity of NK cells. It is not considered that the upregulation of KIRs by IL2 results in enhanced ability to sort target cells, such as viral infected cells from uninfected cells, according to major histocompatibility complex (MHC) class I expression.

NK cytotoxicity decreases in patients with some autoimmune diseases, such as systemic lupus erythematosus, Crohn’s disease, and rheumatoid arthritis (RA). It is known that patients with these diseases have increased susceptibility to microbial infection. For RA, a clinicopathological study of 81 patients at necropsy found that the cause of death was related to infection in 23.5% of cases. Patients with RA have increased susceptibility to Mycobacterium tuberculosis (TB) owing to treatment with corticosteroids or immunosuppressant drugs and the defective immune status of patients with RA. In humans, CD4+ T cells are thought to have a major role in antimycobacterial immunity. Additionally, several lineages of lymphocytes, such as CD8+ T cells or NK cells, may play a crucial part in the protection against TB infection through cytotoxic responses. Thus it is important from a clinical viewpoint to investigate the immune response of NK cells obtained from the patients who are highly susceptible to microbes such as TB. However, as KIR expression on NK cells has not been analysed in patients with RA.

Table 1 Percentage of killer cell inhibitory receptor expressing cells in the peripheral blood mononuclear cells of patients with rheumatoid arthritis and healthy controls.

<table>
<thead>
<tr>
<th>Cell population (%)</th>
<th>Healthy controls (n=14)</th>
<th>Patients with RA (n=25)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD16 CD158a</td>
<td>1.68 (1.43)</td>
<td>1.13 (1.22)</td>
</tr>
<tr>
<td>CD16 CD158b</td>
<td>5.52 (4.58)</td>
<td>6.61 (3.76)</td>
</tr>
<tr>
<td>CD8 CD158a</td>
<td>1.03 (0.58)</td>
<td>0.61 (0.48)*</td>
</tr>
<tr>
<td>CD8 CD158b</td>
<td>2.51 (1.66)</td>
<td>2.40 (1.47)</td>
</tr>
</tbody>
</table>

*p<0.05 in Mann-Whitney’s U test.
RA we analysed this and the regulation of KIR expression by IL2 in patients with RA compared with healthy subjects.

**Methods**

**HEALTHY SUBJECTS AND PATIENTS**

Twenty five patients (19 female, six male) with flares of RA as defined by the revised criteria of the American College of Rheumatology were included in this study. The characteristics of these patients, given as means (SD), were as follows: age 56.3 (11.4) years (range 23–72), disease duration 8.1 (6.2) years (range 2–24), erythrocyte sedimentation rate 78 (41) mm/1st h (range 36–113), CH50 (serum complement titre/50% haemolytic unit of complement) 36.9 (7.0) U/ml (range 26–52), anatomical stage 2.3 (1.3), and functional class 2.1 (0.9). All were receiving non-steroidal anti-inflammatory drugs. Two were also taking bismuth, three gold sodium thiomalate, and four prednisolone (2.5–7.5 mg/day). None was receiving methotrexate. Peripheral blood from 14 healthy, age matched volunteers (53.3 (14.8) years) was used.

**REAGENTS**

Fluorescein isothiocyanate (FITC) conjugated antihuman CD8, FITC-antihuman CD16, phycoerythrin (PE) conjugated antihuman CD158a (EB6), and PE conjugated antihuman CD158b (GL183) were purchased from Immunotech, Marseille, France. Recombinant human IL2 was obtained from Pharmabiotechnology, Hanover, Germany.

**CELLS**

Peripheral blood mononuclear cells obtained from 14 healthy subjects and 25 patients with RA were separated from heparinised blood by Lymphoprep (Nyegaard, Oslo, Norway) gradient centrifugation. They were incubated in a culture dish in a humidified 5% CO2/95% air atmosphere at 37°C for 60 minutes. After the incubation, non-adherent cells were collected and washed twice in phosphate buffered saline (PBS).

**CELL CULTURE**

One million cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (Biological Industries, Israel) in tissue culture dishes (Becton Dickinson, Franklin, NJ). The cell cultures were incubated in medium only, or medium with IL2 at 50 or 200 U/ml, in a humidified 5% CO2/95% air atmosphere at 37°C for 48 hours. After the incubation, non-adherent cells were collected and washed twice in phosphate buffered saline (PBS).

**CELL PHENOTYPE**

Surface phenotyping was carried out by a two colour immunofluorescence staining technique, with isotype-specific mouse antihuman antibody conjugated with either FITC or PE. Each sample of stained cells was suspended in 0.5 ml PBS and analysed by flow cytometry. Lymphocyte subsets were identified by gating analysis, and fluorescence profiles were obtained for 10 000 cells of each sample.

---

**Figure 1** Regulation of CD158a and CD158b expression by interleukin 2 (IL2) in healthy subjects and patients with rheumatoid arthritis (RA). *p<0.05 versus healthy subjects in each cell population. (A) Although the population of CD16+ cells was significantly increased by treatment with IL2 (versus no treatment in each group), the increase of CD16+ cells was significantly less in RA than in healthy controls. (B) The increase of CD16+CD158a+ cells was significantly less in RA than in healthy controls by treatment with IL2 at 50 and 200 U/ml. (C) The increase of CD16+CD158b+ cells was significantly less in RA than in healthy controls for treatment with IL2 at 200 U/ml but not 50 U/ml. (D) The increase of CD8+CD158a+ cells was significantly less in RA than in healthy controls for treatment with IL2 at both 50 and 200 U/ml. (E) The increase of CD8+CD158b+ cells was lower in patients with RA than in healthy subjects, though the difference was not significant.
Negative controls for each experiment were performed with FITC- and PE-labelled mouse IgG.

**STATISTICAL ANALYSIS**

Data are expressed as mean (SD) values. All data were collected in a computer database and analysed with the StatView-J 4.02 program (Abacus Concept, Berkeley, CA, USA). The Mann-Whitney U test was performed for each set of surface antigens. For all statistical tests p<0.05 was regarded as significant.

**Results**

**CD158a AND CD158b EXPRESSION IN THE PATIENTS WITH RA**

Table 1 summarises the degree of CD158a/b expression. The percentage of the number of cells expressing CD158a/b and CD8 or CD16 is shown. There was no significant difference of CD158a or CD158b expression on the CD16+ cells between the patients with RA and healthy subjects. In contrast, the percentage of CD158a expression on the CD8+ cells was lower in the patients with RA than in healthy subjects, though there was no significant difference in CD158b expression.

**REGULATION OF CD158a AND CD158b EXPRESSION BY IL2 IN HEALTHY SUBJECTS AND THE PATIENTS WITH RA**

The population of CD16+ (an activatory receptor for NK cells) cells was significantly increased in the patients with RA by treatment with IL2, as shown in a previous study (fig 1A). At the same time, the percentage of CD16+CD158a+b+ cells was increased in healthy controls (figs 1B and C), as shown in a recent report.

In this study we assessed the difference of the response of KIR expression (CD158a/b) to IL2 between healthy controls and patients with RA. Figures 1B and C show that the response to IL2 was significantly reduced in patients with RA compared with that in healthy controls. There was a significant difference in CD16+CD158a+ cells when IL2 was used at 50 and 200 U/ml, but a significant difference in CD16+CD158b+ cells only for IL2 at 200 U/ml. The KIRs were expressed on T cells, so we further analysed the response of KIRs on CD8+ cells (figs 1D and E). The percentage of CD8+CD158a+ cells that increased in response to IL2 was significantly less in patients with RA than in healthy controls (fig 1D). The increase of CD8+CD158b+ cells was lower in patients with RA than in healthy subjects, though the difference was not significant (fig 1E).

**Discussion**

The identification of KIRs raises several interesting questions. How is the expression of KIRs affected by cytokines such as IL2, which activates cytotoxicity, and IL4, which inhibits IL2 induced cytotoxicity? Recently, we showed that IL2, but not interferon-γ or IL4, upregulates the expression of CD158a/b molecules on lymphocytes. Because IL2 enhances NK cytotoxicity, we now consider that IL2 may enhance the ability of NK cells to sort the target cells according to MHC class I expression by the upregulation of KIR expression. It is important from a clinical viewpoint that KIRs are upregulated in response to microbial infections. However, KIR expression has not been analysed in patients with RA, though they are known to have low NK activity and high susceptibility to microbes.

As far as we know, this is the first investigation to measure the expression of KIRs (CD158a/b) in patients with RA, and to show that the population of CD8+CD158a+ cells is lower in patients with RA than in healthy subjects, and that the upregulation of CD158a/b by treatment with IL2 is weaker in patients with RA than in healthy subjects.

The role of NK cells in the propagation of rheumatoid inflammation remains unclear. NK cell function in peripheral blood of patients with RA may be normal or depressed. Disease modifying drugs, especially gold treatment, resulted in enhanced circulating NK cell activity as well as a decrease in RA disease activity. Thus it is important to analyse the functional disorders of NK cells in RA. In this study a less upregulated rate of KIRs by IL2 was found in the patients with RA. It has been shown that IL2 treatment did not restore the NK activity of peripheral blood of patients with RA to normal levels, though the NK activity was enhanced by IL2 treatment in vitro. Possibly, this is one of the factors that induce the disorder of NK cytotoxicity in RA. However, the association between less upregulation of KIRs and the pathogenesis of RA is still obscure.

A series of immune dysfunctions plays a part not only in the development of inflammatory joints but also in the high susceptibility to microbes in RA. The low response of KIRs to IL2 may be related to a TB infection. T cell mediated, acquired immune response to TB is a complex response believed to involve a variety of cell subsets. In patients with TB, IL2 administration induced the augmentation of NK cell cytotoxicity as well as the potentiation of the antimicrobial cellular immune response to TB. Our finding of a low response of KIRs to IL2 suggests that patients with RA may be highly susceptible to TB. This has certainly been shown, even when the patients with RA are not treated with immunosuppressive drugs.

The significant role of KIR expression on T cells rather than NK cells is still unclear; however, it is speculated that it may be related to the ability to escape the attack by cytotoxic T cells which react with autoantigens. There was no significant difference in the CD158a or CD158b expression on CD16+ cells between patients with RA and healthy subjects. In contrast, the rate of CD158a expression on the CD8+ cells was lower in the patients with RA than in healthy subjects. The consequences of the low CD158a expression on CD8+ cells in RA are still not known; however, this phenomenon may be associated with the self attacking mechanism in autoimmune diseases.
Expression of killer cell inhibitory receptors in RA

Further studies will be required to examine this possibility.

Finally, we showed the expression of KIRs (CD158a/b) in patients with RA, and demonstrated that the population of CD8+CD158a+ cells was reduced in patients with RA compared with healthy subjects, and that the upregulation of CD158a/b by the treatment with IL2 was weaker in patients with RA than in healthy subjects.

We thank TS Oda and N Kuribayashi for excellent assistance.


10.1136/ard.60.2.166